ImmunityBio (IBRX) Competitors $2.81 -0.06 (-2.09%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.82 +0.02 (+0.53%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX vs. BPMC, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and LNTHShould you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. ImmunityBio vs. Its Competitors Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Lantheus ImmunityBio (NASDAQ:IBRX) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends. Does the media favor IBRX or BPMC? In the previous week, Blueprint Medicines had 1 more articles in the media than ImmunityBio. MarketBeat recorded 10 mentions for Blueprint Medicines and 9 mentions for ImmunityBio. Blueprint Medicines' average media sentiment score of 1.23 beat ImmunityBio's score of 0.35 indicating that Blueprint Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Blueprint Medicines 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IBRX or BPMC more profitable? Blueprint Medicines has a net margin of -27.70% compared to ImmunityBio's net margin of -1,310.30%. ImmunityBio's return on equity of 0.00% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets ImmunityBio-1,310.30% N/A -121.88% Blueprint Medicines -27.70%-64.60%-17.22% Do analysts recommend IBRX or BPMC? ImmunityBio currently has a consensus price target of $12.25, suggesting a potential upside of 335.94%. Blueprint Medicines has a consensus price target of $128.25, suggesting a potential downside of 0.81%. Given ImmunityBio's stronger consensus rating and higher possible upside, equities research analysts clearly believe ImmunityBio is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.24 Which has stronger earnings and valuation, IBRX or BPMC? Blueprint Medicines has higher revenue and earnings than ImmunityBio. Blueprint Medicines is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$14.74M168.26-$413.56M-$0.58-4.84Blueprint Medicines$508.82M16.41-$67.09M-$2.47-52.35 Which has more volatility and risk, IBRX or BPMC? ImmunityBio has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Do institutionals and insiders hold more shares of IBRX or BPMC? 8.6% of ImmunityBio shares are owned by institutional investors. 76.8% of ImmunityBio shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryImmunityBio beats Blueprint Medicines on 9 of the 16 factors compared between the two stocks. Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBRX vs. The Competition Export to ExcelMetricImmunityBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.53B$2.97B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-4.8420.7128.1320.27Price / Sales168.26288.39428.6398.72Price / CashN/A42.8637.4658.16Price / Book-4.937.638.045.49Net Income-$413.56M-$55.05M$3.18B$250.45M7 Day Performance4.07%8.43%3.62%4.78%1 Month Performance-11.91%5.42%4.05%7.67%1 Year Performance-57.55%2.03%30.00%16.43% ImmunityBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBRXImmunityBio2.356 of 5 stars$2.81-2.1%$12.25+335.9%-58.1%$2.53B$14.74M-4.84590News CoverageAnalyst ForecastBPMCBlueprint Medicines1.2248 of 5 stars$128.16+0.0%$128.06-0.1%+9.8%$8.28B$562.12M-51.89640Positive NewsInsider TradeBBIOBridgeBio Pharma4.5848 of 5 stars$43.16-3.8%$58.85+36.3%+72.8%$8.20B$221.90M-12.23400Analyst UpgradeVRNAVerona Pharma PLC American Depositary Share2.3736 of 5 stars$94.53+0.8%$101.10+7.0%+394.0%$8.05B$42.28M-47.2730Trending NewsAnalyst ForecastROIVRoivant Sciences2.8364 of 5 stars$11.27-1.1%$17.50+55.3%+1.1%$7.66B$29.05M-45.08860Analyst UpgradeELANElanco Animal Health1.5088 of 5 stars$14.28-0.1%$15.17+6.2%+9.0%$7.09B$4.44B19.309,000News CoverageRVMDRevolution Medicines4.5764 of 5 stars$36.79-0.3%$67.58+83.7%-12.3%$6.85B$11.58M-9.20250LEGNLegend Biotech3.3981 of 5 stars$35.74+3.2%$76.20+113.2%-19.7%$6.57B$627.24M-60.582,609Analyst ForecastGRFSGrifols3.9722 of 5 stars$8.88+0.2%$10.30+16.0%+10.1%$6.11B$7.81B7.5923,822News CoverageTGTXTG Therapeutics3.7966 of 5 stars$35.97-2.0%$40.80+13.4%+73.4%$5.71B$329M149.88290News CoveragePositive NewsAnalyst UpgradeLNTHLantheus4.5774 of 5 stars$82.21+0.9%$130.50+58.7%-34.2%$5.69B$1.53B23.36700News CoveragePositive News Related Companies and Tools Related Companies BPMC Alternatives BBIO Alternatives VRNA Alternatives ROIV Alternatives ELAN Alternatives RVMD Alternatives LEGN Alternatives GRFS Alternatives TGTX Alternatives LNTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IBRX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBRX Stock Alerts